利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

268 条记录 (耗时 0.054 秒)

    Tumor-associated peptide binding promiscuously to human leukocyte antigen (HLA) class II molecules
    205.
    发明公开
    Tumor-associated peptide binding promiscuously to human leukocyte antigen (HLA) class II molecules 审中-公开
    肿瘤相关肽与人类白细胞抗原（HLA）II类分子混杂结合

    公开(公告)号：EP2138509A1

    公开(公告)日：2009-12-30

    申请号：EP09011317.6

    申请日：2006-09-05

    申请人： Immatics Biotechnologies GmbH

    发明人： Dengjel, Jörn

    IPC分类号： C07K14/47 ,  A61K39/00

    CPC分类号： C07K14/4748 ,  A61K38/00 ,  C07K14/7051

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 具体而言，本发明涉及癌症的免疫治疗。 本发明还涉及作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其他肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 具体而言，本发明涉及49种新的肽序列，其衍生自可用于引发抗肿瘤免疫应答的疫苗组合物的人类肿瘤细胞系的HLA II类分子。

    AN MHC-MOLEKÜLE BINDENDE TUMOR-ASSOZIIERTE PEPTIDE
    208.
    发明公开
    AN MHC-MOLEKÜLE BINDENDE TUMOR-ASSOZIIERTE PEPTIDE 审中-公开
    MHC-MOLEKÜLEBINDENDE肿瘤 - ASSOZERERTE肽

    公开(公告)号：EP1606308A2

    公开(公告)日：2005-12-21

    申请号：EP04722556.0

    申请日：2004-03-23

    申请人： Immatics Biotechnologies GmbH

    发明人： RAMMENSEE, Hans, Georg ,  STEVANOVIC, Stefan ,  WEINSCHENK, Toni ,  LEMMEL, Claudia ,  DENGJEL, Jörn ,  SCHOOR, Oliver

    IPC分类号： C07K7/00

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/78

    摘要： The invention relates to a tumour-associated peptide having an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 101 from the associated sequence protocol, said peptide being able to bind to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of said peptides and the nucleic acids coding therefor, for producing a medicament and for the treatment of tumour diseases and/or adenomatous diseases. The invention further relates to a pharmaceutical composition comprising at least one of said peptides.

    摘要翻译： 本发明涉及具有选自相关序列方案的SEQ ID No.1至SEQ ID No.101的氨基酸序列的肿瘤相关肽，所述肽能够结合人类主要分子 组织相容性复合体（MHC）I类。本发明还涉及所述肽及其编码核酸在生产药物和治疗肿瘤疾病和/或腺瘤疾病中的用途。 本发明进一步涉及包含至少一种所述肽的药物组合物。